Subphenotypes of self-reported symptoms and outcomes in long COVID : a prospective cohort study with latent class analysis
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To characterise subphenotypes of self-reported symptoms and outcomes (SRSOs) in postacute sequelae of COVID-19 (PASC).
DESIGN: Prospective, observational cohort study of subjects with PASC.
SETTING: Academic tertiary centre from five clinical referral sources.
PARTICIPANTS: Adults with COVID-19 ≥20 days before enrolment and presence of any new self-reported symptoms following COVID-19.
EXPOSURES: We collected data on clinical variables and SRSOs via structured telephone interviews and performed standardised assessments with validated clinical numerical scales to capture psychological symptoms, neurocognitive functioning and cardiopulmonary function. We collected saliva and stool samples for quantification of SARS-CoV-2 RNA via quantitative PCR.
OUTCOMES MEASURES: Description of PASC SRSOs burden and duration, derivation of distinct PASC subphenotypes via latent class analysis (LCA) and relationship with viral load.
RESULTS: We analysed baseline data for 214 individuals with a study visit at a median of 197.5 days after COVID-19 diagnosis. Participants reported ever having a median of 9/16 symptoms (IQR 6-11) after acute COVID-19, with muscle-aches, dyspnoea and headache being the most common. Fatigue, cognitive impairment and dyspnoea were experienced for a longer time. Participants had a lower burden of active symptoms (median 3 (1-6)) than those ever experienced (p<0.001). Unsupervised LCA of symptoms revealed three clinically active PASC subphenotypes: a high burden constitutional symptoms (21.9%), a persistent loss/change of smell and taste (20.6%) and a minimal residual symptoms subphenotype (57.5%). Subphenotype assignments were strongly associated with self-assessments of global health, recovery and PASC impact on employment (p<0.001) as well as referral source for enrolment. Viral persistence (5.6% saliva and 1% stool samples positive) did not explain SRSOs or subphenotypes.
CONCLUSIONS: We identified three distinct PASC subphenotypes. We highlight that although most symptoms progressively resolve, specific PASC subpopulations are impacted by either high burden of constitutional symptoms or persistent olfactory/gustatory dysfunction, requiring prospective identification and targeted preventive or therapeutic interventions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
BMJ open - 14(2024), 3 vom: 14. März, Seite e077869 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kitsios, Georgios D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2023-077869 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369751639 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369751639 | ||
| 003 | DE-627 | ||
| 005 | 20240318234754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2023-077869 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1335.xml |
| 035 | |a (DE-627)NLM369751639 | ||
| 035 | |a (NLM)38485476 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kitsios, Georgios D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Subphenotypes of self-reported symptoms and outcomes in long COVID |b a prospective cohort study with latent class analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: To characterise subphenotypes of self-reported symptoms and outcomes (SRSOs) in postacute sequelae of COVID-19 (PASC) | ||
| 520 | |a DESIGN: Prospective, observational cohort study of subjects with PASC | ||
| 520 | |a SETTING: Academic tertiary centre from five clinical referral sources | ||
| 520 | |a PARTICIPANTS: Adults with COVID-19 ≥20 days before enrolment and presence of any new self-reported symptoms following COVID-19 | ||
| 520 | |a EXPOSURES: We collected data on clinical variables and SRSOs via structured telephone interviews and performed standardised assessments with validated clinical numerical scales to capture psychological symptoms, neurocognitive functioning and cardiopulmonary function. We collected saliva and stool samples for quantification of SARS-CoV-2 RNA via quantitative PCR | ||
| 520 | |a OUTCOMES MEASURES: Description of PASC SRSOs burden and duration, derivation of distinct PASC subphenotypes via latent class analysis (LCA) and relationship with viral load | ||
| 520 | |a RESULTS: We analysed baseline data for 214 individuals with a study visit at a median of 197.5 days after COVID-19 diagnosis. Participants reported ever having a median of 9/16 symptoms (IQR 6-11) after acute COVID-19, with muscle-aches, dyspnoea and headache being the most common. Fatigue, cognitive impairment and dyspnoea were experienced for a longer time. Participants had a lower burden of active symptoms (median 3 (1-6)) than those ever experienced (p<0.001). Unsupervised LCA of symptoms revealed three clinically active PASC subphenotypes: a high burden constitutional symptoms (21.9%), a persistent loss/change of smell and taste (20.6%) and a minimal residual symptoms subphenotype (57.5%). Subphenotype assignments were strongly associated with self-assessments of global health, recovery and PASC impact on employment (p<0.001) as well as referral source for enrolment. Viral persistence (5.6% saliva and 1% stool samples positive) did not explain SRSOs or subphenotypes | ||
| 520 | |a CONCLUSIONS: We identified three distinct PASC subphenotypes. We highlight that although most symptoms progressively resolve, specific PASC subpopulations are impacted by either high burden of constitutional symptoms or persistent olfactory/gustatory dysfunction, requiring prospective identification and targeted preventive or therapeutic interventions | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a virology | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Blacka, Shawna |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, Jana J |e verfasserin |4 aut | |
| 700 | 1 | |a Mirza, Taaha |e verfasserin |4 aut | |
| 700 | 1 | |a Naqvi, Asma |e verfasserin |4 aut | |
| 700 | 1 | |a Gentry, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Golubykh, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Qurashi, Hafiz |e verfasserin |4 aut | |
| 700 | 1 | |a Dodia, Akash |e verfasserin |4 aut | |
| 700 | 1 | |a Risbano, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Benigno, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Emir, Birol |e verfasserin |4 aut | |
| 700 | 1 | |a Weinstein, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Bramson, Candace |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Szigethy, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Mellors, John W |e verfasserin |4 aut | |
| 700 | 1 | |a Methe, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Sciurba, Frank C |e verfasserin |4 aut | |
| 700 | 1 | |a Nouraie, Seyed Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Alison |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2011 |g 14(2024), 3 vom: 14. März, Seite e077869 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:3 |g day:14 |g month:03 |g pages:e077869 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2023-077869 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 3 |b 14 |c 03 |h e077869 | ||